N Asdaghi1, J I Coulter2, J Modi3, M C Camden2, A Qazi2, M Goyal4, T Rundek5, S B Coutts6. 1. From the Departments of Clinical Neurosciences (N.A., J.I.C., M.C.C., A.Q., M.G., S.B.C.) Division of Cerebrovascular Disease (N.A., T.R.), Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida. nasdaghi@med.miami.edu. 2. From the Departments of Clinical Neurosciences (N.A., J.I.C., M.C.C., A.Q., M.G., S.B.C.). 3. Radiology (J.M., M.G., S.B.C.). 4. From the Departments of Clinical Neurosciences (N.A., J.I.C., M.C.C., A.Q., M.G., S.B.C.) Radiology (J.M., M.G., S.B.C.). 5. Division of Cerebrovascular Disease (N.A., T.R.), Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida. 6. From the Departments of Clinical Neurosciences (N.A., J.I.C., M.C.C., A.Q., M.G., S.B.C.) Radiology (J.M., M.G., S.B.C.) Hotchkiss Brain Institute (S.B.C.), University of Calgary, Calgary, Alberta, Canada.
Abstract
BACKGROUND AND PURPOSE: Acute statin therapy improves neurologic outcome and diminishes infarct growth in animal models of stroke. Clinical studies suggest that premorbid and early statin use is associated with improved outcome after major stroke. We studied the association between statin therapy and radiographic and clinical outcomes in patients with high-risk TIA and minor stroke. MATERIALS AND METHODS: Patients with high-risk TIA and minor stroke (NIHSS ≤3) were prospectively enrolled within 24 hours of symptom onset. Patients were followed clinically for 3 months, and a subset had a repeat MR imaging at 90 days. RESULTS: Of 418 patients, 23% were prescribed statins before their stroke. Statins were continued in 20% and initiated in 42%. Patients on prior statin therapy were older and more hypertensive, treated with aspirin, and more likely to have symptomatic carotid disease compared with those not on statin. Adjusting for these differences, prior statin treatment was not associated with DWI positivity (adjusted OR = 1.3; 95% CI, 0.77-2.1; P = .32) or smaller median baseline infarct volume, 1.1 mL (interquartile range = 4) versus 1 mL (interquartile range = 2.5; P = .56). Early or continued treatment with statins did not improve the risk of clinical deterioration (adjusted OR = 0.66; 95% CI, 0.27-1.6; P = .35) or poor functional outcome at 3 months (adjusted OR = 0.66; 95% CI, 0.35-1.24; P = .19). CONCLUSIONS: Prestroke or early-stroke statin therapy was not associated with a reduction in the number of DWI lesions, infarct volume, or improved clinical or functional outcome at 3 months. The effect of acute statin treatment in patients with ischemic stroke/TIA remains unclear and needs further investigation.
BACKGROUND AND PURPOSE: Acute statin therapy improves neurologic outcome and diminishes infarct growth in animal models of stroke. Clinical studies suggest that premorbid and early statin use is associated with improved outcome after major stroke. We studied the association between statin therapy and radiographic and clinical outcomes in patients with high-risk TIA and minor stroke. MATERIALS AND METHODS:Patients with high-risk TIA and minor stroke (NIHSS ≤3) were prospectively enrolled within 24 hours of symptom onset. Patients were followed clinically for 3 months, and a subset had a repeat MR imaging at 90 days. RESULTS: Of 418 patients, 23% were prescribed statins before their stroke. Statins were continued in 20% and initiated in 42%. Patients on prior statin therapy were older and more hypertensive, treated with aspirin, and more likely to have symptomatic carotid disease compared with those not on statin. Adjusting for these differences, prior statin treatment was not associated with DWI positivity (adjusted OR = 1.3; 95% CI, 0.77-2.1; P = .32) or smaller median baseline infarct volume, 1.1 mL (interquartile range = 4) versus 1 mL (interquartile range = 2.5; P = .56). Early or continued treatment with statins did not improve the risk of clinical deterioration (adjusted OR = 0.66; 95% CI, 0.27-1.6; P = .35) or poor functional outcome at 3 months (adjusted OR = 0.66; 95% CI, 0.35-1.24; P = .19). CONCLUSIONS: Prestroke or early-stroke statin therapy was not associated with a reduction in the number of DWI lesions, infarct volume, or improved clinical or functional outcome at 3 months. The effect of acute statin treatment in patients with ischemic stroke/TIA remains unclear and needs further investigation.
Authors: Shelagh B Coutts; Jayesh Modi; Shiel K Patel; Andrew M Demchuk; Mayank Goyal; Michael D Hill Journal: Stroke Date: 2012-02-02 Impact factor: 7.914
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: Jayme C Kosior; Sherif Idris; Dar Dowlatshahi; Mohamed Alzawahmah; Muneer Eesa; Pranshu Sharma; Sarah Tymchuk; Michael D Hill; Richard I Aviv; Richard Frayne; Andrew M Demchuk Journal: Int J Stroke Date: 2011-01-28 Impact factor: 5.266
Authors: Steven J Shook; Rishi Gupta; Nirav A Vora; Andrew L Tievsky; Irene Katzan; Derk W Krieger Journal: J Neuroimaging Date: 2006-10 Impact factor: 2.486
Authors: Negar Asdaghi; Michael D Hill; Jonathan I Coulter; Kenneth S Butcher; Jayesh Modi; Abdul Qazi; Mayank Goyal; Andrew M Demchuk; Shelagh B Coutts Journal: Stroke Date: 2013-08-01 Impact factor: 7.914
Authors: Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; William J Sasiela; Michael Szarek; Peter Ganz; Peter Libby Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Myles Horton; Jayesh Modi; Shiel K Patel; Andrew M Demchuk; Mayank Goyal; Michael D Hill; Shelagh B Coutts Journal: PLoS One Date: 2013-06-21 Impact factor: 3.240
Authors: Nicolas Poupore; Dan Strat; Tristan Mackey; Katherine Brown; Ashley Snell; Thomas I Nathaniel Journal: Lipids Health Dis Date: 2020-05-06 Impact factor: 3.876